PMID- 24498860
OWN - NLM
STAT- MEDLINE
DCOM- 20140806
LR  - 20220310
IS  - 1365-3083 (Electronic)
IS  - 0300-9475 (Linking)
VI  - 80
IP  - 1
DP  - 2014 Jul
TI  - Changes in serum levels of brain derived neurotrophic factor and nerve growth 
      factor-beta in schizophrenic patients before and after treatment.
PG  - 36-42
LID - 10.1111/sji.12158 [doi]
AB  - Schizophrenia is one of the most debilitating diseases among psychiatric 
      disorders. Recent studies suggest the existence of effective immunological 
      changes in the pathophysiology of this disease. The purpose of the current study 
      was to determine the changes in serum levels of Brain Derived Neurotrophic Factor 
      (BDNF) and Nerve Growth Factor-beta (NGF) in schizophrenic patients before 
      treatment and 40 days after treatment. In this case-control study, serum levels 
      of BDNF and NGF were measured by ELISA in 26 patients with schizophrenia and 26 
      healthy controls. All patients were treated with clozapine or risperidone for 40 
      days. A positive and negative syndrome scale (PANSS) questionnaire has been used 
      to recognize the severity of the disease and to assess the response to treatment. 
      Neurotrophin concentrations were compared before and after the treatment and with 
      control groups using paired t-test and ANOVA test. BDNF and NGF levels in the 
      case group were more than levels after treatment, but these differences were 
      significant only for NGF. Concentrations in both neurotrophins were higher than 
      the control group. The statistically significant difference was observed between 
      changes in the NGF levels in the case and the control group, while no significant 
      difference was seen in changes of BDNF. The main conclusion to be drawn from this 
      study was that the increase in BDNF and particularly NGF may have an important 
      role in causing schizophrenia. And possibly drugs clozapine and risperidone help 
      to treat the disease by reducing the concentration of Neurotrophins.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Ajami, A
AU  - Ajami A
AD  - Department of Immunology and Microbiology, School of Medicine, Mazandaran 
      University of Medical Sciences, Sari, Iran.
FAU - Hosseini, S H
AU  - Hosseini SH
FAU - Taghipour, M
AU  - Taghipour M
FAU - Khalilian, A
AU  - Khalilian A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nerve Growth Factor/*blood
MH  - Recurrence
MH  - Schizophrenia/*blood/drug therapy
MH  - Social Class
EDAT- 2014/02/07 06:00
MHDA- 2014/08/07 06:00
CRDT- 2014/02/07 06:00
PHST- 2013/12/11 00:00 [received]
PHST- 2014/01/29 00:00 [accepted]
PHST- 2014/02/07 06:00 [entrez]
PHST- 2014/02/07 06:00 [pubmed]
PHST- 2014/08/07 06:00 [medline]
AID - 10.1111/sji.12158 [doi]
PST - ppublish
SO  - Scand J Immunol. 2014 Jul;80(1):36-42. doi: 10.1111/sji.12158.